Elizabeth Yeu Lin, Chief Medical Officer of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), filed a Form 4 on September 9, 2026, disclosing the sale of common stock on September 4, 2026, pursuant to two separate Rule 10b5-1 trading plans.
Key Highlights
- Reporting person: Elizabeth Yeu Lin, Chief Medical Officer of Tarsus Pharmaceuticals, Inc.
- Direct sales: 5,387 shares sold at $85 and 5,386 shares sold at $90 on September 4, 2026, both directly owned.
- Indirect sales via Spouse's Roth IRA: 1,590 shares sold at $85 and 1,590 shares sold at $90 on September 4, 2026.
- Post-transaction direct ownership: 7,933 shares directly held following the first direct sale; 2,547 shares directly held following the second direct sale.
- Indirect holdings remaining: 1,590 shares held indirectly by Spouse's Roth IRA after reported transactions; 12,040 shares held indirectly through a 401(k) Plan with no transactions reported.
- Trading plans: Direct sales conducted under a Rule 10b5-1 plan adopted May 29, 2026; indirect sales conducted under a separate Rule 10b5-1 plan adopted June 1, 2026.
Tarsus Pharmaceuticals CMO Share Dispositions and Beneficial Ownership Details
According to the filing, all sales reported were effected automatically under pre-established Rule 10b5-1 trading plans. The direct sales of 5,387 shares at $85 and 5,386 shares at $90 were made pursuant to a plan the reporting person adopted on May 29, 2026. The indirect sales of 1,590 shares at $85 and 1,590 shares at $90, held through the reporting person's spouse's Roth IRA, were made pursuant to a separate plan adopted on June 1, 2026. Tarsus Pharmaceuticals is a pharmaceutical company; its common stock is listed on NASDAQ under the ticker TARS.
Following the reported transactions, the filing discloses that Elizabeth Yeu Lin directly held 2,547 shares of common stock. Separately, 1,590 shares remained held indirectly through the Spouse's Roth IRA, and 12,040 shares were held indirectly through a 401(k) Plan, with no transactions reported for the 401(k) holdings. The Form 4 was signed by Jeffrey Farrow as Attorney-in-Fact on September 9, 2026.
What Was Disclosed
The filing disclosed four separate common stock sale transactions by the Chief Medical Officer of Tarsus Pharmaceuticals on September 4, 2026, covering both directly held shares and shares held indirectly through a spouse's Roth IRA, all executed under Rule 10b5-1 plans.



Please wait processing your request...